Home・Aandelen Lijst・Merck & Co Inc.

Merck & Co Inc.

Open

SectorGezondheidszorg

127.89 0.42

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

125.21

Max

129.94

Belangrijke statistieken
By Trading Economics
Inkomsten	-7.2B -4.2B
Verkoop	-114M 16B
K/W Sectorgemiddelde	36.834 64.641
EPS	-1.28
Dividendrendement	2.5
Winstmarge	-26.053
Werknemers	73,000
EBITDA	-6.4B -2B

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+7.18% upside

Dividenden
By Acuity
Dividendrendement Sectorgemiddelde	2.50% 2.31%
Volgende Winsten	4 aug 2026
Volgende dividenddatum	7 okt 2026
Volgende Ex Dividend datum	15 sep 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	35B 307B
Vorige openingsprijs	127.47
Vorige sluitingsprijs	127.89

Nieuwssentiment

By Acuity

21%

79%

48 / 340 Rangschikking in Healthcare

Merck & Co Inc. Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 aug 2026, 20:03 UTC

News

Social Media

Merck & Co Inc shares are lower as the company prepares for Q2 earnings on August 4, despite reporting $16.29 billion in last quarter revenues.

31 jul 2026, 23:16 UTC

Merck & Co Inc shares are higher in after-market hours, maintaining a position near the upper end of their one-month range amid varied broader market performance.

30 jul 2026, 20:09 UTC

Merck & Co Inc shares are declining, with no specific news identified. Broader market volatility is influenced by mixed economic signals and jobless claims.

29 jul 2026, 23:41 UTC

Merck & Co Inc shares are lower in after-market hours, driven by weakness in the Pharmaceuticals sub-sector. The stock remains above its 20-day moving average.

28 jul 2026, 23:01 UTC

Merck & Co Inc shares are higher in after-market hours, maintaining stability above the 20-day moving average and near the upper end of their one-month range.

27 jul 2026, 20:06 UTC

Social Media

Merck & Co Inc shares are lower, testing the $132 level amid broader market declines and declining oil prices impacting Treasury yields ahead of the Fed meeting.

24 jul 2026, 18:56 UTC

News

Social Media

Merck & Co Inc. announced a strategy to enhance access to its HIV prevention drug Alimatravir across 129 countries, boosting shares during Friday's session.

22 jul 2026, 19:46 UTC

Social Media

Merck & Co Inc shares are higher, supported by strong contract performance valued at $1,000. The stock remains near its one-month high amid broader market challenges.

21 jul 2026, 19:56 UTC

News

Social Media

Merck & Co. Inc. shares are rising following positive Phase 3 trial results for its once-weekly oral HIV treatment regimen, islatravir and lenacapavir.

20 jul 2026, 20:02 UTC

Social Media

Merck & Co. shares are lower as the pharmaceutical sector faces pressure. The company plans to price Lipfendra at $10.50 per day.

Peer Vergelijking

Prijswijziging

Merck & Co Inc. Prognose

Koersdoel

By TipRanks

7.18% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 136.94 USD 7.18%

Hoogste 155 USD

Laagste 100 USD

Gebaseerd op 18 Wall Street-analisten die 12-maands prijsdoelen bieden voor Merck & Co Inc. - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

18 ratings

Buy

Hold

Sell

Gebaseerd op 18 analisten die aandelenratings hebben gegeven aan Merck & Co Inc. - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

48 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.